Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Comparing Immune Reconstitution in Post-Transplant Cy Myeloablative Vs Reduced Intensity Transplants: Notable Trends in Monocyte Population

Manan Shah, Mandi Zhu, Rathan Kumar, Malith Karunasiri, Lotus Neidemire-Colley, Nicholas Yuhasz, Elizabeth Miller, Marcos de Lima, Parvathi Ranganathan, Hannah Choe

Blood (2024) 144 (Supplement 1): 7336.

https://doi.org/10.1182/blood-2024-201863

Published: 2024

Journal Articles

Bromodomain/Extra-Terminal Inhibition (BETi) and Ruxolitinib: Immune Profiling Insights from Human Samples in Acute Gvhd

Manan Shah, Rathan Kumar, Lotus Neidemire-Colley, Mandi Zhu, Nicholas Yuhasz, Malith Karunasiri, Parvathi Ranganathan, Hannah Choe

Blood (2024) 144 (Supplement 1): 4906.

https://doi.org/10.1182/blood-2024-199900

Published: 2024

Journal Articles

Inhibition of Bromodomain and Extraterminal Domain (BET) Proteins Alleviates Chronic Graft- Versus -Host-Disease Via Modulating the CXCR5/CXCL13 Axis

Rathan Kumar, Lotus Neidermire-Colley, Charlie Spencer, David Aslaner, Yandi Gao, Simran Surana, Matthew W Gorr, Katiri Snyder, Malith Karunasiri, Loren E Wold, Gideon Bollag, Ben Powell, Hannah Choe, Parvathi Ranganathan

Blood (2023) 142 (Supplement 1): 2047.

https://doi.org/10.1182/blood-2023-182354

Published: 2023

Journal Articles

Prohibitin Is a Substrate of PRMT5 in T Cells and Is a Potential Therapeutic Target for Acute Graft-Versus-Host Disease

Katiri Snyder, Lotus Neidemire-Colley, Yandi Gao, Parvathi Ranganathan

Blood (2022) 140 (Supplement 1): 10229–10230.

https://doi.org/10.1182/blood-2022-168141

Published: 2022

Journal Articles

CRISPR/CAS9 Gene Editing of MIR155HG in Primary Human T Cells to Prevent Acute Graft-Versus-Host Disease

Shrijan Khanal, Lotus Neidemire-Colley, Kara M Braunreiter, Katiri Snyder, Yandi Gao, Sonu Kalyan, Meisam Naeimi Kararoudi, Molly Erin Duszynski, Mengna Chi, Punam Malik, Hannah Choe, Ramiro Garzon, Parvathi Ranganathan

Blood (2022) 140 (Supplement 1): 10200–10201.

https://doi.org/10.1182/blood-2022-159599

Published: 2022

Journal Articles

Advanced Machine Learning Techniques to Predict Gvhd Occurrence and Severity with High Accuracy

Hannah Choe, Nicholas Yuhasz, Greer Elizabeth Miller, Me'kayla Travis, Avinash Karanth, Kyle Shifflet, Parvathi Ranganathan

Blood (2022) 140 (Supplement 1): 7658–7659.

https://doi.org/10.1182/blood-2022-167454

Published: 2022

Journal Articles

Modulating Endothelial Cells with EGFL7 to Diminish aGVHD after Allogeneic Bone Marrow Transplantation in Mice

Martin Guimond, Moutuaata Moutuou, Chinmayee Goda, Nathalie Sell, Sonu Kaylan, Malith Karunasiri, Rohan SUDHIR Kulkarni, Marie Goulard, Sofia Kovovich, Eric Naumann, Antoire Ackaoui, Charles-Etienne Bigras, Francis Daudelin, Alex Ruddich, Ramiro Garzon, Parvathi Ranganathan, Adrienne M. Dorrance

Blood (2021) 138 (Supplement 1): 4786.

https://doi.org/10.1182/blood-2021-152740

Published: 2021

Journal Articles

Bromodomain and Extraterminal (BET) Domain Inhibition with PLX51107 and PLX2853 Improves Survival and Decreases Acute GVHD Severity in Murine Models

Hannah K. Choe, MD, Yandi Gao, MS, Katiri Snyder, BS, Ben Powell, PhD, Gideon Bollag, PhD, Parvathi Ranganathan, PhD

Blood (2019) 134 (Supplement_1): 4429.

https://doi.org/10.1182/blood-2019-122455

Published: 2019

Journal Articles

EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia (AML)

Marius Bill, MD PhD, Aparna Pathmanathan, Malith Karunasiri, Changxian Shen, Matthew Burke, Parvathi Ranganathan, PhD, Dimitrios Papaioannou, MD, Nina C. Zitzer, DVM, Katiri Snyder, Allison LaRocco, Allison Walker, Zachary Brannan, Ansel P. Nalin, Aharon G. Freud, MD PhD, Mikhail Dikov, Xiaoli Zhang, PhD, Clara D. Bloomfield, MD, Ramiro Garzon, MD, Adrienne M. Dorrance, PhD

Blood (2019) 134 (Supplement_1): 2546.

https://doi.org/10.1182/blood-2019-131856

Published: 2019

Journal Articles

PRMT5 Is Upregulated in Activated T Cells and Is a Novel Therapeutic Target for Acute Gvhd

Parvathi Ranganathan, PhD, Katiri Snyder, Nina Zizter, Hannah K. Choe, MD, Robert A Baiocchi, MD PhD, Kris Vaddi, PhD

Blood (2018) 132 (Supplement 1): 2034.

https://doi.org/10.1182/blood-2018-99-114835

Published: 2018

Journal Articles

Response Rates, Non-Relapse Mortality, and Financial Implications of Transplant-Associated Thrombotic Microangiopathy Treated with Eculizumab

Blood (2017) 130 (Supplement 1): 1932.

https://doi.org/10.1182/blood.V130.Suppl_1.1932.1932

Published: 2017

Journal Articles

Transplant Associated Thrombotic Microangiopathy (TA-TMA) Commonly Occurs after Steroid-Refractory or Dependent Gastrointestinal (GI) Graft Versus Host Disease (GVHD) and Contributes to Post-Transplant Morbidity

Blood (2017) 130 (Supplement 1): 4483.

https://doi.org/10.1182/blood.V130.Suppl_1.4483.4483

Published: 2017

Journal Articles

Pirfenidone: a breath of fresh air for cGVHD

Parvathi Ranganathan

Blood (2017) 129 (18): 2463–2464.

https://doi.org/10.1182/blood-2017-03-772103

Published: 2017

Journal Articles

A Phase 1 Clinical Trial of Selinexor in Combination with Decitabine in Patients with Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

Bhavana Bhatnagar, DO, Rebecca B. Klisovic, MD, Alison R. Walker, MD MPH, Sumithra Vasu, MBBS, Alice S. Mims, MD MSCR, Katherine J. Walsh, MD, Gregory K. Behbehani, MD PhD, James S. Blachly, MD, Molly Vittorio, Qiuhong Zhao, Amy S. Ruppert, MAS, Shelley Orwick, BS, Parvathi Ranganathan, PhD, John C. Byrd, MD, William Blum, MD, Ramiro Garzon, MD

Blood (2016) 128 (22): 1651.

https://doi.org/10.1182/blood.V128.22.1651.1651

Published: 2016

Journal Articles

miR-146b antagomir–treated human Tregs acquire increased GVHD inhibitory potency

Yunjie Lu, Keli L. Hippen, Amanda L. Lemire, Jian Gu, Weizhi Wang, Xuhao Ni, Parvathi Ranganathan, Bruce L. Levine, James L. Riley, Carl H. June, Laurence A. Turka, David H. Munn, Ramiro Garzon, Ling Lu, Bruce R. Blazar

Blood (2016) 128 (10): 1424–1435.

https://doi.org/10.1182/blood-2016-05-714535

Published: 2016

Includes: Supplemental data

Journal Articles

Preclinical Development of LNA Antimir-155 (MRG-106) in Acute Myeloid Leukemia

Nina C. Zitzer, DVM, Parvathi Ranganathan, PhD, Brent A Dickinson, BA, Aimee L Jackson, PhD, David M Rodman, MD, Carlo M. Croce, MD, Guido Marcucci, MD, Ramiro Garzon, MD

Blood (2015) 126 (23): 3802.

https://doi.org/10.1182/blood.V126.23.3802.3802

Published: 2015

Journal Articles

Next Generation XPO1 Inhibitor Shows Improved Efficacy and In Vivo Tolerability in Hematologic Malignancies

Blood (2015) 126 (23): 317.

https://doi.org/10.1182/blood.V126.23.317.317

Published: 2015

Journal Articles

MiR-155 Impacts T Cell Migration in Acute Graft-Versus-Host Disease (aGVHD)

Nina C. Zitzer, DVM, Patricia A. Taylor, DVM, Apollinaire Ngankeu, Yvonne A. Efebera, MD MPH, Steven M. Devine, MD, Bruce R. Blazar, MD, Ramiro Garzon, MD, Parvathi Ranganathan, PhD

Blood (2015) 126 (23): 3080.

https://doi.org/10.1182/blood.V126.23.3080.3080

Published: 2015

Journal Articles

Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia

Parvathi Ranganathan, Xueyan Yu, Ramasamy Santhanam, Jessica Hofstetter, Alison Walker, Katherine Walsh, Bhavana Bhatnagar, Rebecca Klisovic, Sumithira Vasu, Mitch A. Phelps, Steven Devine, Sharon Shacham, Michael Kauffman, Guido Marcucci, William Blum, Ramiro Garzon

Blood (2015) 125 (17): 2689–2692.

https://doi.org/10.1182/blood-2014-10-607648

Published: 2015

Includes: Supplemental data

Journal Articles

Implications of the miR-10 family in chemotherapy response of NPM1 -mutated AML

Violaine Havelange, Parvathi Ranganathan, Susan Geyer, Deedra Nicolet, Xiaomeng Huang, Xueyan Yu, Stefano Volinia, Steven M. Kornblau, Michael Andreeff, Carlo M. Croce, Guido Marcucci, Clara D. Bloomfield, Ramiro Garzon

Blood (2014) 123 (15): 2412–2415.

https://doi.org/10.1182/blood-2013-10-532374

Published: 2014

Includes: Supplemental data

NARROW

Comparing Immune Reconstitution in Post-Transplant Cy Myeloablative Vs Reduced Intensity Transplants: Notable Trends in Monocyte Population

Bromodomain/Extra-Terminal Inhibition (BETi) and Ruxolitinib: Immune Profiling Insights from Human Samples in Acute Gvhd

Inhibition of Bromodomain and Extraterminal Domain (BET) Proteins Alleviates Chronic Graft- Versus -Host-Disease Via Modulating the CXCR5/CXCL13 Axis

Prohibitin Is a Substrate of PRMT5 in T Cells and Is a Potential Therapeutic Target for Acute Graft-Versus-Host Disease

CRISPR/CAS9 Gene Editing of MIR155HG in Primary Human T Cells to Prevent Acute Graft-Versus-Host Disease

Advanced Machine Learning Techniques to Predict Gvhd Occurrence and Severity with High Accuracy

Modulating Endothelial Cells with EGFL7 to Diminish aGVHD after Allogeneic Bone Marrow Transplantation in Mice

Bromodomain and Extraterminal (BET) Domain Inhibition with PLX51107 and PLX2853 Improves Survival and Decreases Acute GVHD Severity in Murine Models

EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia (AML)

PRMT5 Is Upregulated in Activated T Cells and Is a Novel Therapeutic Target for Acute Gvhd

Response Rates, Non-Relapse Mortality, and Financial Implications of Transplant-Associated Thrombotic Microangiopathy Treated with Eculizumab

Transplant Associated Thrombotic Microangiopathy (TA-TMA) Commonly Occurs after Steroid-Refractory or Dependent Gastrointestinal (GI) Graft Versus Host Disease (GVHD) and Contributes to Post-Transplant Morbidity

Pirfenidone: a breath of fresh air for cGVHD

A Phase 1 Clinical Trial of Selinexor in Combination with Decitabine in Patients with Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

miR-146b antagomir–treated human Tregs acquire increased GVHD inhibitory potency

Preclinical Development of LNA Antimir-155 (MRG-106) in Acute Myeloid Leukemia

Next Generation XPO1 Inhibitor Shows Improved Efficacy and In Vivo Tolerability in Hematologic Malignancies

MiR-155 Impacts T Cell Migration in Acute Graft-Versus-Host Disease (aGVHD)

Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia

Implications of the miR-10 family in chemotherapy response of NPM1 -mutated AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only